| Oct 29 |
JPMorgan views Edwards Lifesciences TAVR data positively
|
| Oct 28 |
Bernstein Lifts Edwards Lifesciences Rating, Sees Balanced Risk-Reward in Tavr Market
|
| Oct 28 |
Edwards Lifesciences upgraded to outperform by Bernstein
|
| Oct 28 |
Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
|
| Oct 28 |
International Markets and Edwards Lifesciences (EW): A Deep Dive for Investors
|
| Oct 27 |
Edwards Lifesciences price target raised to $85 from $80 at Barclays
|
| Oct 26 |
Earnings Beat: Edwards Lifesciences Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
|
| Oct 25 |
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
|
| Oct 25 |
EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
|
| Oct 25 |
Edwards Lifesciences Corp (EW) Q3 2024 Earnings Call Highlights: Strong Growth in TMTT Sales ...
|
